Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.
2.

Identification of multiple species and subpopulations among Australian clinical Sporothrix isolates using whole genome sequencing.

New D, Beukers AG, Kidd SE, Merritt AJ, Weeks K, van Hal SJ, Arthur I.

Med Mycol. 2019 Oct 1;57(7):905-908. doi: 10.1093/mmy/myy126.

PMID:
30500920
3.

Invasive Fungal Sinusitis Presenting as Acute Posterior Ischemic Optic Neuropathy.

Ghabrial R, Ananda A, van Hal SJ, Thompson EO, Larsen SR, Heydon P, Gupta R, Cherepanoff S, Rodriguez M, Halmagyi GM.

Neuroophthalmology. 2017 Nov 7;42(4):209-214. doi: 10.1080/01658107.2017.1392581. eCollection 2018 Aug.

4.

Global Scale Dissemination of ST93: A Divergent Staphylococcus aureus Epidemic Lineage That Has Recently Emerged From Remote Northern Australia.

van Hal SJ, Steinig EJ, Andersson P, Holden MTG, Harris SR, Nimmo GR, Williamson DA, Heffernan H, Ritchie SR, Kearns AM, Ellington MJ, Dickson E, de Lencastre H, Coombs GW, Bentley SD, Parkhill J, Holt DC, Giffard PM, Tong SYC.

Front Microbiol. 2018 Jul 9;9:1453. doi: 10.3389/fmicb.2018.01453. eCollection 2018.

5.

Recommendations To Address the Difficulties Encountered When Determining Linezolid Resistance from Whole-Genome Sequencing Data.

Beukers AG, Hasman H, Hegstad K, van Hal SJ.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00613-18. doi: 10.1128/AAC.00613-18. Print 2018 Aug.

6.

Defining the Role of the Environment in the Emergence and Persistence of vanA Vancomycin-Resistant Enterococcus (VRE) in an Intensive Care Unit: A Molecular Epidemiological Study.

Lee AS, White E, Monahan LG, Jensen SO, Chan R, van Hal SJ.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):668-675. doi: 10.1017/ice.2018.29. Epub 2018 Apr 3.

PMID:
29611491
7.

Relentless spread and adaptation of non-typeable vanA vancomycin-resistant Enterococcus faecium: a genome-wide investigation.

van Hal SJ, Beukers AG, Timms VJ, Ellem JA, Taylor P, Maley MW, Newton PJ, Ferguson JK, Lee A, Chen SC, Sintchenko V.

J Antimicrob Chemother. 2018 Jun 1;73(6):1487-1491. doi: 10.1093/jac/dky074.

PMID:
29566173
8.

Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia.

Holmes NE, Robinson JO, van Hal SJ, Munckhof WJ, Athan E, Korman TM, Cheng AC, Turnidge JD, Johnson PDR, Howden BP; VANESSA study group, on behalf of the Australasian Society for Infectious Diseases (ASID) Clinical Research Network (CRN).

BMC Infect Dis. 2018 Mar 5;18(1):107. doi: 10.1186/s12879-018-3011-2.

9.

Cronobacter sakazakii Infection from Expressed Breast Milk, Australia.

McMullan R, Menon V, Beukers AG, Jensen SO, van Hal SJ, Davis R.

Emerg Infect Dis. 2018 Feb;24(2):393-394. doi: 10.3201/eid2402.171411.

10.

Failure of daptomycin β-Lactam combination therapy to prevent resistance emergence in Enterococcus faecium.

Menon V, Davis R, Shackel N, Espedido BA, Beukers AG, Jensen SO, van Hal SJ.

Diagn Microbiol Infect Dis. 2018 Feb;90(2):120-122. doi: 10.1016/j.diagmicrobio.2017.10.017. Epub 2017 Nov 29.

PMID:
29195768
11.

Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.

Burgard M, Sandaradura I, van Hal SJ, Stacey S, Hennig S.

Clin Pharmacokinet. 2018 Aug;57(8):1017-1027. doi: 10.1007/s40262-017-0610-9.

PMID:
29134570
12.

Personalized Medicine and Infectious Disease Management.

Jensen SO, van Hal SJ.

Trends Microbiol. 2017 Nov;25(11):875-876. doi: 10.1016/j.tim.2017.09.006. Epub 2017 Sep 29.

PMID:
28969882
13.

Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach.

Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A.

Intensive Care Med. 2017 Oct;43(10):1464-1475. doi: 10.1007/s00134-017-4878-x. Epub 2017 Jul 21. Review.

PMID:
28733718
14.

Acute unilateral peripheral vestibulopathy in neurosyphilis.

Young AS, Carroll AS, Welgampola MS, McCluskey PJ, van Hal SJ, Thompson EO, Burn J, Fulham MJ, Halmagyi GM.

J Neurol Sci. 2017 Jul 15;378:55-58. doi: 10.1016/j.jns.2017.04.038. Epub 2017 Apr 23.

PMID:
28566179
15.

Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.

Chavada R, Ghosh N, Sandaradura I, Maley M, Van Hal SJ.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02535-16. doi: 10.1128/AAC.02535-16. Print 2017 May.

16.

Polyclonal emergence of vanA vancomycin-resistant Enterococcus faecium in Australia.

van Hal SJ, Espedido BA, Coombs GW, Howden BP, Korman TM, Nimmo GR, Gosbell IB, Jensen SO.

J Antimicrob Chemother. 2017 Apr 1;72(4):998-1001. doi: 10.1093/jac/dkw539.

PMID:
28031272
17.

MALDI-TOF MS meets WGS in a VRE outbreak investigation.

Schlebusch S, Price GR, Gallagher RL, Horton-Szar V, Elbourne LD, Griffin P, Venter DJ, Jensen SO, Van Hal SJ.

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):495-499. doi: 10.1007/s10096-016-2824-4. Epub 2016 Nov 26.

PMID:
27889877
18.

Evolutionary dynamics of Enterococcus faecium reveals complex genomic relationships between isolates with independent emergence of vancomycin resistance.

van Hal SJ, Ip CLC, Ansari MA, Wilson DJ, Espedido BA, Jensen SO, Bowden R.

Microb Genom. 2016 Jan 19;2(1). doi: 10.1099/mgen.0.000048.

19.

Mucormycosis in Australia: contemporary epidemiology and outcomes.

Kennedy KJ, Daveson K, Slavin MA, van Hal SJ, Sorrell TC, Lee A, Marriott DJ, Chapman B, Halliday CL, Hajkowicz K, Athan E, Bak N, Cheong E, Heath CH, Morrissey CO, Kidd S, Beresford R, Blyth C, Korman TM, Robinson JO, Meyer W, Chen SC; Australia and New Zealand Mycoses Interest Group of the Australasian Society for Infectious Diseases.

Clin Microbiol Infect. 2016 Sep;22(9):775-781. doi: 10.1016/j.cmi.2016.01.005. Epub 2016 Jan 20.

20.

When sepsis persists: a review of MRSA bacteraemia salvage therapy.

Kullar R, Sakoulas G, Deresinski S, van Hal SJ.

J Antimicrob Chemother. 2016 Mar;71(3):576-86. doi: 10.1093/jac/dkv368. Epub 2015 Nov 12. Review.

PMID:
26565015
21.

Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.

Davis JS, Sud A, O'Sullivan MVN, Robinson JO, Ferguson PE, Foo H, van Hal SJ, Ralph AP, Howden BP, Binks PM, Kirby A, Tong SYC; Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA) study group; Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA) study group, Tong S, Davis J, Binks P, Majumdar S, Ralph A, Baird R, Gordon C, Jeremiah C, Leung G, Brischetto A, Crowe A, Dakh F, Whykes K, Kirkwood M, Sud A, Menon M, Somerville L, Subedi S, Owen S, O'Sullivan M, Liu E, Zhou F, Robinson O, Coombs G, Ferguson P, Ralph A, Liu E, Pollet S, Van Hal S, Foo H, Van Hal S, Davis R.

Clin Infect Dis. 2016 Jan 15;62(2):173-180. doi: 10.1093/cid/civ808. Epub 2015 Sep 8.

PMID:
26349552
22.

The use of whole-genome sequencing for molecular epidemiology and antimicrobial surveillance: identifying the role of IncX3 plasmids and the spread of blaNDM-4-like genes in the Enterobacteriaceae.

Espedido BA, Dimitrijovski B, van Hal SJ, Jensen SO.

J Clin Pathol. 2015 Oct;68(10):835-8. doi: 10.1136/jclinpath-2015-203044. Epub 2015 Jun 8.

PMID:
26056157
23.

"Tolerance" of misused terminology? Enforcing standardized phenotypic definitions.

Dimitrijovski B, Jensen SO, Espedido BA, van Hal SJ.

MBio. 2015 Apr 28;6(3):e00446-15. doi: 10.1128/mBio.00446-15. No abstract available.

24.

Convergent adaptation in the dominant global hospital clone ST239 of methicillin-resistant Staphylococcus aureus.

Baines SL, Holt KE, Schultz MB, Seemann T, Howden BO, Jensen SO, van Hal SJ, Coombs GW, Firth N, Powell DR, Stinear TP, Howden BP.

MBio. 2015 Mar 3;6(2):e00080. doi: 10.1128/mBio.00080-15.

25.

Treatment of methicillin-resistant Staphylococcus aureus: vancomycin and beyond.

Holmes NE, Tong SY, Davis JS, van Hal SJ.

Semin Respir Crit Care Med. 2015 Feb;36(1):17-30. doi: 10.1055/s-0034-1397040. Epub 2015 Feb 2. Review.

PMID:
25643268
26.

Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.

Chau MM, Kong DC, van Hal SJ, Urbancic K, Trubiano JA, Cassumbhoy M, Wilkes J, Cooper CM, Roberts JA, Marriott DJ, Worth LJ.

Intern Med J. 2014 Dec;44(12b):1364-88. doi: 10.1111/imj.12600. Review.

PMID:
25482746
27.

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.

Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, Bajel A, van Hal SJ, Chen SC, Milliken ST, Morrissey CO, Tam CS, Szer J, Weinkove R, Slavin MA.

Intern Med J. 2014 Dec;44(12b):1283-97. doi: 10.1111/imj.12595. Review.

PMID:
25482741
28.

Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.

van Hal SJ, Gilroy NM, Morrissey CO, Worth LJ, Szer J, Tam CS, Chen SC, Thursky KA, Slavin MA.

Intern Med J. 2014 Dec;44(12b):1277-82. doi: 10.1111/imj.12594. Review.

PMID:
25482740
29.

Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.

Espedido BA, Jensen SO, van Hal SJ.

J Antimicrob Chemother. 2015 Mar;70(3):797-801. doi: 10.1093/jac/dku455. Epub 2014 Nov 17.

PMID:
25406295
30.

Urgent cerebrospinal fluid analysis: is it necessary?

Sivagnanam S, Chan RC, Janto C, Van Hal SJ.

Pathology. 2014 Dec;46(7):649-50. doi: 10.1097/PAT.0000000000000174. No abstract available.

PMID:
25393258
31.

Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia--authors' response.

Foo H, Chater M, Maley M, van Hal SJ.

J Antimicrob Chemother. 2014 Nov;69(11):3166. doi: 10.1093/jac/dku329. Epub 2014 Aug 12. No abstract available.

PMID:
25118271
32.

Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.

Ghosh N, Chavada R, Maley M, van Hal SJ.

Clin Microbiol Infect. 2014 Dec;20(12):O1098-105. doi: 10.1111/1469-0691.12695. Epub 2014 Jul 12.

33.

Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study.

van Hal SJ, Chen SC, Sorrell TC, Ellis DH, Slavin M, Marriott DM.

J Antimicrob Chemother. 2014 Aug;69(8):2210-4. doi: 10.1093/jac/dku124. Epub 2014 Apr 30.

PMID:
24788656
34.

Reply to "Technical notes on the correct configuration of the Alfred 60/AST device for the detection of urinary tract infections".

Lahanas S, Stathopoulos G, Chan R, van Hal SJ.

J Clin Microbiol. 2014 May;52(5):1807. doi: 10.1128/JCM.00356-14. No abstract available.

35.

Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia.

Foo H, Chater M, Maley M, van Hal SJ.

J Antimicrob Chemother. 2014 Aug;69(8):2252-7. doi: 10.1093/jac/dku107. Epub 2014 Apr 16.

PMID:
24744303
36.

Is there still a place for itraconazole prophylaxis in high-risk hematology patients?

van Hal SJ, Larsen SR, Chan RC.

Ann Hematol. 2014 Sep;93(9):1617-8. doi: 10.1007/s00277-013-1998-4. Epub 2014 Jan 10. No abstract available.

PMID:
24408157
37.

In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale?

van Hal SJ, Steen JA, Espedido BA, Grimmond SM, Cooper MA, Holden MT, Bentley SD, Gosbell IB, Jensen SO.

J Antimicrob Chemother. 2014 Feb;69(2):363-7. doi: 10.1093/jac/dkt354. Epub 2013 Sep 18.

38.

Evaluation of the Alfred 60/AST device as a screening test for urinary tract infections.

Lahanas S, Stathopoulos G, Chan RC, van Hal SJ.

J Clin Microbiol. 2013 Oct;51(10):3406-8. doi: 10.1128/JCM.01126-13. Epub 2013 Jul 24.

39.

Reply to Parra-Ruiz.

van Hal SJ, Fowler VG Jr.

Clin Infect Dis. 2013 Oct;57(8):1219-20. doi: 10.1093/cid/cit460. Epub 2013 Jul 15. No abstract available.

PMID:
23861360
40.

Reply to "Vancomycin-induced nephrotoxicity".

van Hal SJ, Paterson DL, Lodise TP.

Antimicrob Agents Chemother. 2013 May;57(5):2436. doi: 10.1128/AAC.00320-13. No abstract available.

41.

Whole genome sequence analysis of the first Australian OXA-48-producing outbreak-associated Klebsiella pneumoniae isolates: the resistome and in vivo evolution.

Espedido BA, Steen JA, Ziochos H, Grimmond SM, Cooper MA, Gosbell IB, van Hal SJ, Jensen SO.

PLoS One. 2013;8(3):e59920. doi: 10.1371/journal.pone.0059920. Epub 2013 Mar 29.

42.

Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

van Hal SJ, Fowler VG Jr.

Clin Infect Dis. 2013 Jun;56(12):1779-88. doi: 10.1093/cid/cit178. Epub 2013 Mar 19.

43.

Staphylococcus aureus colonisation: some questions answered.

Gosbell IB, van Hal SJ.

Lancet Infect Dis. 2013 May;13(5):380-1. doi: 10.1016/S1473-3099(13)70048-3. Epub 2013 Mar 6. No abstract available.

PMID:
23473662
44.

"Probable contaminants" no more: rapid identification of Gram-positive rods leads to improved clinical care.

McKew G, Watson B, Chan R, van Hal SJ.

J Clin Microbiol. 2013 May;51(5):1641. doi: 10.1128/JCM.03358-12. Epub 2013 Feb 13. No abstract available.

45.

Vancomycin therapeutics and monitoring: a contemporary approach.

Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ, Holmes NE, Howden BP, Paterson DL.

Intern Med J. 2013 Feb;43(2):110-9. doi: 10.1111/imj.12036. Review.

PMID:
23185970
46.

Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.

van Hal SJ, Paterson DL, Lodise TP.

Antimicrob Agents Chemother. 2013 Feb;57(2):734-44. doi: 10.1128/AAC.01568-12. Epub 2012 Nov 19. Review.

47.

Clostridium difficile testing: have we got it right?

Su WY, Mercer J, Van Hal SJ, Maley M.

J Clin Microbiol. 2013 Jan;51(1):377-8. doi: 10.1128/JCM.02189-12. Epub 2012 Oct 24. No abstract available.

48.

Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in Indigenous Australians.

Tong SY, van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD; Australian New Zealand Cooperative on Outcomes in Staphylococcal Sepsis.

BMC Infect Dis. 2012 Oct 9;12:249. doi: 10.1186/1471-2334-12-249.

49.

Predictors of mortality in Staphylococcus aureus Bacteremia.

van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB.

Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11. Review.

50.

The impact of bacterial and viral co-infection in severe influenza.

Blyth CC, Webb SA, Kok J, Dwyer DE, van Hal SJ, Foo H, Ginn AN, Kesson AM, Seppelt I, Iredell JR; ANZIC Influenza Investigators; COSI Microbiological Investigators.

Influenza Other Respir Viruses. 2013 Mar;7(2):168-76. doi: 10.1111/j.1750-2659.2012.00360.x. Epub 2012 Apr 6.

Supplemental Content

Loading ...
Support Center